Novartis AG (NVS) Chairman Stresses Need For R&D Investment
3/24/2014 7:53:54 AM
Novartis AG needs to continue investing in research to develop new drugs that national health-care systems are willing to pay for, a task that gets harder as generic versions of older medicines become available, the company's chairman said.
Joerg Reinhardt, who assumed his role in August, says the benchmark for evaluating drugs is constantly rising as branded medicines lose patent protection, allowing for less-expensive copies to enter the market.
Help employers find you! Check out all the jobs and post your resume.
comments powered by